ClinicalTrials.gg

Angioedemas, Hereditary clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 171 studies for Angioedemas, Hereditary across more than 10 countries. 24 are recruiting or about to start. 160 of them are mainly about Angioedemas, Hereditary (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Status

Completed
115
Recruiting
13
Active, not recruiting
10
Terminated
9
Withdrawn
5
Enrolling by invitation
5

Phase

Phase 3
60
Phase 2
35
Phase 1
22
Phase 4
10
Early Phase 1
1

Where

United States
84
Germany
60
United Kingdom
51
Canada
48
Italy
43
France
38

Who develops what

Add Angioedemas, Hereditary to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 8 companies, 8 with this as their studies’ main aim; 4 with a live phase 3 study; 4 primary completions in the next 12 months. Compare BioCryst Pharmaceuticals, Chiesi Farmaceutici and CSL here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
donidalorsenApproved: US 2025 · EU 2026☆ Track2 live phase-3 studies: NCT07298447, NCT05392114Ionis Pharmaceuticals, Inc.
navenibart☆ Track2 live phase-3 studies: NCT07204938, NCT06842823BioCryst Pharmaceuticals
deucrictibant☆ Track3 live phase-3 studies: NCT06679881, NCT07266805, NCT05396105Pharvaris Netherlands B.V.
onvuzosiran sodium☆ Track2 live phase-3 studies: NCT06960213, NCT07428499ADARx Pharmaceuticals, Inc.

The 4 in phase 3 with the nearest primary completion, of 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.donidalorsen · Ionis Pharmaceuticals, Inc. · Phase 3 main aimNCT05392114 A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) — primary endpoint: Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by Severity · 154 enrolled
  • Dec 2026 est.navenibart · BioCryst Pharmaceuticals · Phase 3 main aimNCT06842823 A Study of Navenibart in Participants With Hereditary Angioedema — primary endpoint: Number of time-normalized investigator-confirmed HAE attacks during the 6-month Treatment Period. · 157 enrolled
  • Jun 2027 est.deucrictibant · Pharvaris Netherlands B.V. · Phase 3 main aimNCT07266805 Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency — primary endpoint: Part 1: Time-normalized number of Investigator-confirmed AAE-C1INH attacks during Treatment Phase · 48 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Angioedemas, Hereditary studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

10studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 10, phase 3 first

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger. 7 (54%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (8%) take healthy volunteers.

Recruiting studies that take each age, of 13
AgeWomenMen
102 (15%)2 (15%)
1812 (92%)12 (92%)
3012 (92%)12 (92%)
4012 (92%)12 (92%)
5012 (92%)12 (92%)
6512 (92%)12 (92%)
7512 (92%)12 (92%)
859 (69%)9 (69%)

Across all 171 studies, recruiting or not: 33% stop at 75 or younger and 27% at 65; 60% take children; 0% are for women only and 3% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Angioedemas, Hereditary studies take

Of 46 phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 15 mo4–9 · 13 studies——
Phase 219 mo11–35 · 17 studies——
Phase 322 mo16–33 · 46 studies22 mo16–33 · 46 studies—
Observational43 mo36–52 · 27 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 171. Browse all 171 → or search them.